VIAF

Virtual International Authority File

Search

Leader     00000nz a2200037n 45 0
001     WKP|Q57914374  (VIAF cluster)  (Authority/Source Record)
003     WKP
005     20241020233148.0
008     241020nneanz||abbn n and d
035 ‎‡a  (WKP)Q57914374‏
024 ‎‡a  0000-0001-9821-7635‏ ‎‡2  orcid‏
024 ‎‡a  6603010117‏ ‎‡2  scopus‏
035 ‎‡a  (OCoLC)Q57914374‏
100 0 ‎‡a  Francisco J Blanco Garcia‏ ‎‡c  researcher, ORCID id # 0000-0001-9821-7635‏ ‎‡9  en‏
375 ‎‡a  1‏ ‎‡2  iso5218‏
400 0 ‎‡a  Francisco J Blanco Garcia‏ ‎‡c  wetenschapper‏ ‎‡9  nl‏
670 ‎‡a  Author's A Phase II Trial of Lutikizumab, an Anti-Interleukin-1α/β Dual Variable Domain Immunoglobulin, in Knee Osteoarthritis Patients With Synovitis‏
670 ‎‡a  Author's Amentadione from the Alga <i>Cystoseira usneoides</i> as a Novel Osteoarthritis Protective Agent in an Ex Vivo Co-Culture OA Model‏
670 ‎‡a  Author's Catabolic events in osteoarthritic cartilage‏
670 ‎‡a  Author's Cohort profile: The Applied Public-Private Research enabling OsteoArthritis Clinical Headway (IMI-APPROACH) study: a 2-year, European, cohort study to describe, validate and predict phenotypes of osteoarthritis using clinical, imaging and biochemica‏
670 ‎‡a  Author's Culture of limbal stem cells on human amniotic membrane‏
670 ‎‡a  Author's Differential Association of Mitochondrial DNA Haplogroups J and H With the Methylation Status of Articular Cartilage: Potential Role in Apoptosis and Metabolic and Developmental Processes‏
670 ‎‡a  Author's Discovery of an autoantibody signature for the early diagnosis of knee osteoarthritis: data from the Osteoarthritis Initiative‏
670 ‎‡a  Author's Discovery of circulating proteins associated to knee radiographic osteoarthritis‏
670 ‎‡a  Author's Evaluation of 12 GWAS-drawn SNPs as biomarkers of rheumatoid arthritis response to TNF inhibitors. A potential SNP association with response to etanercept‏
670 ‎‡a  Author's Generating Rho-0 Cells Using Mesenchymal Stem Cell Lines.‏
670 ‎‡a  Author's Generation and characterization of human induced pluripotent stem cells (iPSCs) from hand osteoarthritis patient-derived fibroblasts‏
670 ‎‡a  Author's Hif-1α Knockdown Reduces Glycolytic Metabolism and Induces Cell Death of Human Synovial Fibroblasts Under Normoxic Conditions‏
670 ‎‡a  Author's Immortalizing Mesenchymal Stromal Cells from Aged Donors While Keeping Their Essential Features‏
670 ‎‡a  Author's Impaired Metabolic Flexibility in the Osteoarthritis Process: A Study on Transmitochondrial Cybrids‏
670 ‎‡a  Author's Integrative Metabolic Pathway Analysis Reveals Novel Therapeutic Targets in Osteoarthritis‏
670 ‎‡a  Author's Intraarticular Administration Effect of Hydrogen Sulfide on an In Vivo Rat Model of Osteoarthritis‏
670 ‎‡a  Author's Mining the Proteome Associated with Rheumatic and Autoimmune Diseases‏
670 ‎‡a  Author's Mitochondrial DNA in osteoarthritis disease‏
670 ‎‡a  Author's Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases‏
670 ‎‡a  Author's Response to: 'Use of tanezumab for patients with hip and knee osteoarthritis with reference to a randomised clinical trial by Berenbaum and colleagues' by Riddle and Perera‏
670 ‎‡a  Author's RGD-Dendrimer-Poly(L-lactic) Acid Nanopatterned Substrates for the Early Chondrogenesis of Human Mesenchymal Stromal Cells Derived from Osteoarthritic and Healthy Donors‏
670 ‎‡a  Author's School children's backpacks, back pain and back pathologies.‏
670 ‎‡a  Author's Secukinumab in Active Rheumatoid Arthritis: A Phase III Randomized, Double-Blind, Active Comparator- and Placebo-Controlled Study.‏
670 ‎‡a  Author's Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period‏
670 ‎‡a  Author's Tratamiento de lesiones del cartílago articular con terapia celular‏
670 ‎‡a  Author's Versatility of Induced Pluripotent Stem Cells (iPSCs) for Improving the Knowledge on Musculoskeletal Diseases‏
670 ‎‡a  Author's Wnt and RUNX2 mediate cartilage breakdown by osteoarthritis synovial fibroblast-derived ADAMTS-7 and -12‏
909 ‎‡a  (orcid) 0000000198217635‏ ‎‡9  1‏
909 ‎‡a  (scopus) 6603010117‏ ‎‡9  1‏
919 ‎‡a  schoolchildrensbackpacksbackpainandbackpathologies‏ ‎‡A  School children's backpacks, back pain and back pathologies.‏ ‎‡9  1‏
919 ‎‡a  secukinumabinactiverheumatoidarthritisaphase3randomizeddoubleblindactivecomparatorandplacebocontrolledstudy‏ ‎‡A  Secukinumab in Active Rheumatoid Arthritis: A Phase III Randomized, Double-Blind, Active Comparator- and Placebo-Controlled Study.‏ ‎‡9  1‏
919 ‎‡a  subcutaneoustanezumabforosteoarthritisofthehiporkneeefficacyandsafetyresultsfroma24weekrandomisedphase3studywitha24weekfollowupperiod‏ ‎‡A  Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period‏ ‎‡9  1‏
919 ‎‡a  tratamientodelesionesdelcartilagoarticularconterapiacelular‏ ‎‡A  Tratamiento de lesiones del cartílago articular con terapia celular‏ ‎‡9  1‏
919 ‎‡a  versatilityofinducedpluripotentstemcellsipscsforimprovingtheknowledgeonmusculoskeletaldiseases‏ ‎‡A  Versatility of Induced Pluripotent Stem Cells (iPSCs) for Improving the Knowledge on Musculoskeletal Diseases‏ ‎‡9  1‏
919 ‎‡a  wntandrunx2mediatecartilagebreakdownbyosteoarthritissynovialfibroblastderivedadamts7and12‏ ‎‡A  Wnt and RUNX2 mediate cartilage breakdown by osteoarthritis synovial fibroblast-derived ADAMTS-7 and -12‏ ‎‡9  1‏
919 ‎‡a  amentadionefromthealga1cystoseirausneoides1asanovelosteoarthritisprotectiveagentinanexvivococultureoamodel‏ ‎‡A  Amentadione from the Alga <i>Cystoseira usneoides</i> as a Novel Osteoarthritis Protective Agent in an Ex Vivo Co-Culture OA Model‏ ‎‡9  1‏
919 ‎‡a  cultureoflimbalstemcellsonhumanamnioticmembrane‏ ‎‡A  Culture of limbal stem cells on human amniotic membrane‏ ‎‡9  1‏
919 ‎‡a  cohortprofiletheappliedpublicprivateresearchenablingosteoarthritisclinicalheadwayimiapproachstudya2yeareuropeancohortstudytodescribevalidateandpredictphenotypesofosteoarthritisusingclinicalimagingandbiochemica‏ ‎‡A  Cohort profile: The Applied Public-Private Research enabling OsteoArthritis Clinical Headway (IMI-APPROACH) study: a 2-year, European, cohort study to describe, validate and predict phenotypes of osteoarthritis using clinical, imaging and biochemica‏ ‎‡9  1‏
919 ‎‡a  cataboliceventsinosteoarthriticcartilage‏ ‎‡A  Catabolic events in osteoarthritic cartilage‏ ‎‡9  1‏
919 ‎‡a  discoveryofanautoantibodysignaturefortheearlydiagnosisofkneeosteoarthritisdatafromtheosteoarthritisinitiative‏ ‎‡A  Discovery of an autoantibody signature for the early diagnosis of knee osteoarthritis: data from the Osteoarthritis Initiative‏ ‎‡9  1‏
919 ‎‡a  discoveryofcirculatingproteinsassociatedtokneeradiographicosteoarthritis‏ ‎‡A  Discovery of circulating proteins associated to knee radiographic osteoarthritis‏ ‎‡9  1‏
919 ‎‡a  evaluationof12gwasdrawnsnpsasbiomarkersofrheumatoidarthritisresponsetotnfinhibitorsapotentialsnpassociationwithresponsetoetanercept‏ ‎‡A  Evaluation of 12 GWAS-drawn SNPs as biomarkers of rheumatoid arthritis response to TNF inhibitors. A potential SNP association with response to etanercept‏ ‎‡9  1‏
919 ‎‡a  differentialassociationofmitochondrialdnahaplogroupsjandhwiththemethylationstatusofarticularcartilagepotentialroleinapoptosisandmetabolicanddevelopmentalprocesses‏ ‎‡A  Differential Association of Mitochondrial DNA Haplogroups J and H With the Methylation Status of Articular Cartilage: Potential Role in Apoptosis and Metabolic and Developmental Processes‏ ‎‡9  1‏
919 ‎‡a  generatingrho0cellsusingmesenchymalstemcelllines‏ ‎‡A  Generating Rho-0 Cells Using Mesenchymal Stem Cell Lines.‏ ‎‡9  1‏
919 ‎‡a  generationandcharacterizationofhumaninducedpluripotentstemcellsipscsfromhandosteoarthritispatientderivedfibroblasts‏ ‎‡A  Generation and characterization of human induced pluripotent stem cells (iPSCs) from hand osteoarthritis patient-derived fibroblasts‏ ‎‡9  1‏
919 ‎‡a  hif1αknockdownreducesglycolyticmetabolismandinducescelldeathofhumansynovialfibroblastsundernormoxicconditions‏ ‎‡A  Hif-1α Knockdown Reduces Glycolytic Metabolism and Induces Cell Death of Human Synovial Fibroblasts Under Normoxic Conditions‏ ‎‡9  1‏
919 ‎‡a  immortalizingmesenchymalstromalcellsfromageddonorswhilekeepingtheiressentialfeatures‏ ‎‡A  Immortalizing Mesenchymal Stromal Cells from Aged Donors While Keeping Their Essential Features‏ ‎‡9  1‏
919 ‎‡a  phase2trialoflutikizumabanantiinterleukin1αβdualvariabledomainimmunoglobulininkneeosteoarthritispatientswithsynovitis‏ ‎‡A  A Phase II Trial of Lutikizumab, an Anti-Interleukin-1α/β Dual Variable Domain Immunoglobulin, in Knee Osteoarthritis Patients With Synovitis‏ ‎‡9  1‏
919 ‎‡a  impairedmetabolicflexibilityintheosteoarthritisprocessastudyontransmitochondrialcybrids‏ ‎‡A  Impaired Metabolic Flexibility in the Osteoarthritis Process: A Study on Transmitochondrial Cybrids‏ ‎‡9  1‏
919 ‎‡a  integrativemetabolicpathwayanalysisrevealsnoveltherapeutictargetsinosteoarthritis‏ ‎‡A  Integrative Metabolic Pathway Analysis Reveals Novel Therapeutic Targets in Osteoarthritis‏ ‎‡9  1‏
919 ‎‡a  intraarticularadministrationeffectofhydrogensulfideonaninvivoratmodelofosteoarthritis‏ ‎‡A  Intraarticular Administration Effect of Hydrogen Sulfide on an In Vivo Rat Model of Osteoarthritis‏ ‎‡9  1‏
919 ‎‡a  miningtheproteomeassociatedwithrheumaticandautoimmunediseases‏ ‎‡A  Mining the Proteome Associated with Rheumatic and Autoimmune Diseases‏ ‎‡9  1‏
919 ‎‡a  mitochondrialdnainosteoarthritisdisease‏ ‎‡A  Mitochondrial DNA in osteoarthritis disease‏ ‎‡9  1‏
919 ‎‡a  prevalenceofhospitalpcrconfirmedcovid19casesinpatientswithchronicinflammatoryandautoimmunerheumaticdiseases‏ ‎‡A  Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases‏ ‎‡9  1‏
919 ‎‡a  responsetouseoftanezumabforpatientswithhipandkneeosteoarthritiswithreferencetoarandomisedclinicaltrialbyberenbaumandcolleaguesbyriddleandperera‏ ‎‡A  Response to: 'Use of tanezumab for patients with hip and knee osteoarthritis with reference to a randomised clinical trial by Berenbaum and colleagues' by Riddle and Perera‏ ‎‡9  1‏
919 ‎‡a  rgddendrimerpoly50lacticacidnanopatternedsubstratesfortheearlychondrogenesisofhumanmesenchymalstromalcellsderivedfromosteoarthriticandhealthydonors‏ ‎‡A  RGD-Dendrimer-Poly(L-lactic) Acid Nanopatterned Substrates for the Early Chondrogenesis of Human Mesenchymal Stromal Cells Derived from Osteoarthritic and Healthy Donors‏ ‎‡9  1‏
946 ‎‡a  b‏ ‎‡9  1‏
996 ‎‡2  BNC|981058614561306706‏
996 ‎‡2  NUKAT|n 2008127106‏
996 ‎‡2  DNB|114440567X‏
996 ‎‡2  BNE|XX1523412‏
996 ‎‡2  BNE|XX1581534‏
996 ‎‡2  SUDOC|257966358‏
996 ‎‡2  BNC|981058581227006706‏
996 ‎‡2  BNE|XX4879213‏
996 ‎‡2  ISNI|0000000059407754‏
996 ‎‡2  NUKAT|n 2021121714‏
996 ‎‡2  BNE|XX1743318‏
996 ‎‡2  BNC|981058608810606706‏
996 ‎‡2  BNE|XX4988019‏
996 ‎‡2  NSK|000715517‏
996 ‎‡2  NSK|000715516‏
996 ‎‡2  BNE|XX1718812‏
996 ‎‡2  BNE|XX1654963‏
996 ‎‡2  BNC|981060556864906706‏
996 ‎‡2  BNE|XX1700810‏
996 ‎‡2  RERO|A003061759‏
996 ‎‡2  BNE|XX1056077‏
996 ‎‡2  ISNI|000000005985145X‏
996 ‎‡2  BNE|XX949977‏
996 ‎‡2  BNE|XX1004727‏
996 ‎‡2  SUDOC|197737005‏
996 ‎‡2  DNB|1074414314‏
996 ‎‡2  DNB|1027139108‏
996 ‎‡2  SUDOC|235436704‏
996 ‎‡2  BNE|XX1272657‏
996 ‎‡2  NTA|26225798X‏
996 ‎‡2  LC|n 93035645‏
996 ‎‡2  RERO|A003279587‏
996 ‎‡2  ISNI|0000000077168742‏
996 ‎‡2  LC|n 92082465‏
996 ‎‡2  DNB|1056337699‏
996 ‎‡2  J9U|987007426831805171‏
996 ‎‡2  RERO|A026440549‏
996 ‎‡2  DNB|1056420944‏
996 ‎‡2  DNB|1053058217‏
996 ‎‡2  SUDOC|083449086‏
996 ‎‡2  BNE|XX5038580‏
996 ‎‡2  BNC|981058512776306706‏
996 ‎‡2  PLWABN|9810545006905606‏
996 ‎‡2  ISNI|0000000116677946‏
996 ‎‡2  DNB|137042051‏
996 ‎‡2  SUDOC|060160179‏
996 ‎‡2  BNE|XX839237‏
996 ‎‡2  ISNI|0000000060646373‏
996 ‎‡2  SUDOC|082987300‏
996 ‎‡2  DNB|1157162673‏
996 ‎‡2  ISNI|0000000060989851‏
996 ‎‡2  LC|no2019072691‏
996 ‎‡2  NTA|073541842‏
996 ‎‡2  NYNYRILM|58378‏
996 ‎‡2  BIBSYS|90109400‏
996 ‎‡2  BNE|XX5583684‏
996 ‎‡2  ISNI|0000000060650997‏
996 ‎‡2  DNB|1016662564‏
996 ‎‡2  SUDOC|119009633‏
996 ‎‡2  BNE|XX5065196‏
996 ‎‡2  NTA|07312690X‏
996 ‎‡2  ISNI|0000000430499703‏
996 ‎‡2  ISNI|0000000059560417‏
996 ‎‡2  RERO|A020473093‏
996 ‎‡2  DNB|1055686185‏
996 ‎‡2  DNB|1056483148‏
996 ‎‡2  ISNI|0000000506307406‏
996 ‎‡2  BNF|17976917‏
996 ‎‡2  NII|DA17944001‏
996 ‎‡2  NII|DA0823529X‏
996 ‎‡2  BNC|981058527689906706‏
996 ‎‡2  BNE|XX1571899‏
996 ‎‡2  LC|no2022055255‏
996 ‎‡2  J9U|987007314305505171‏
996 ‎‡2  J9U|987007325543005171‏
996 ‎‡2  SUDOC|133158721‏
996 ‎‡2  DNB|1056501448‏
996 ‎‡2  LC|n 2012048845‏
996 ‎‡2  SELIBR|m1r69nmjk12tzn0k‏
996 ‎‡2  ISNI|0000000004502834‏
996 ‎‡2  LC|n 2009046510‏
996 ‎‡2  ISNI|0000000060545820‏
996 ‎‡2  DNB|1172107750‏
996 ‎‡2  BNE|XX4953377‏
996 ‎‡2  BNC|981058512455906706‏
996 ‎‡2  BIBSYS|14037267‏
996 ‎‡2  BNE|XX1204207‏
996 ‎‡2  BNE|XX938170‏
996 ‎‡2  BNC|981060022343506706‏
996 ‎‡2  ISNI|0000000059549955‏
996 ‎‡2  LC|n 2013061800‏
996 ‎‡2  BNE|XX4843611‏
996 ‎‡2  PTBNP|67075‏
996 ‎‡2  DNB|1272201635‏
996 ‎‡2  BNE|XX1168218‏
996 ‎‡2  BNE|XX918846‏
996 ‎‡2  J9U|987007350269605171‏
996 ‎‡2  NTA|336500173‏
996 ‎‡2  BNC|981058609578806706‏
996 ‎‡2  LC|n 00029346‏
996 ‎‡2  ICCU|BVEV064031‏
996 ‎‡2  DNB|1057174890‏
996 ‎‡2  BNE|XX6193939‏
996 ‎‡2  LC|no2009199472‏
996 ‎‡2  ISNI|0000000117510494‏
996 ‎‡2  ISNI|0000000025767479‏
996 ‎‡2  BNE|XX1058483‏
996 ‎‡2  DNB|152598855‏
996 ‎‡2  LC|n 2008066883‏
996 ‎‡2  BNE|XX1151173‏
996 ‎‡2  NTA|069434336‏
996 ‎‡2  BNE|XX836193‏
996 ‎‡2  BNE|XX5180023‏
996 ‎‡2  LC|n 97016763‏
996 ‎‡2  BNE|XX969640‏
996 ‎‡2  ISNI|0000000059581779‏
996 ‎‡2  BNE|XX938959‏
996 ‎‡2  BNC|981058511480206706‏
996 ‎‡2  LC|n 83179694‏
996 ‎‡2  BNE|XX5072463‏
996 ‎‡2  ISNI|0000000060332147‏
996 ‎‡2  DNB|1132144639‏
996 ‎‡2  LC|ns2018002429‏
996 ‎‡2  RERO|A016495628‏
996 ‎‡2  BNE|XX1085656‏
996 ‎‡2  BNE|XX1149738‏
996 ‎‡2  LC|n 2007028576‏
996 ‎‡2  ISNI|0000000109194364‏
996 ‎‡2  JPG|500264292‏
996 ‎‡2  DNB|1056408529‏
996 ‎‡2  NKC|mub2013750423‏
996 ‎‡2  BNF|12142354‏
996 ‎‡2  J9U|987007410005405171‏
996 ‎‡2  BNE|XX5011292‏
996 ‎‡2  BNE|XX5053275‏
996 ‎‡2  BNF|14100021‏
996 ‎‡2  SUDOC|032918690‏
996 ‎‡2  BNE|XX853327‏
996 ‎‡2  BNE|XX5034116‏
996 ‎‡2  NKC|mub2015867414‏
996 ‎‡2  LC|no2011108551‏
996 ‎‡2  RERO|A000111277‏
996 ‎‡2  ISNI|0000000072838196‏
996 ‎‡2  BNE|XX1102926‏
996 ‎‡2  BNE|XX1642117‏
996 ‎‡2  DNB|120429710X‏
996 ‎‡2  NTA|069343659‏
996 ‎‡2  DNB|1057528978‏
996 ‎‡2  DNB|105654743X‏
996 ‎‡2  BNE|XX867560‏
996 ‎‡2  LC|n 2005062865‏
996 ‎‡2  BNE|XX1769598‏
996 ‎‡2  LC|no2024092141‏
996 ‎‡2  DNB|1132548624‏
996 ‎‡2  BNE|XX993132‏
996 ‎‡2  BNE|XX1279656‏
996 ‎‡2  BIBSYS|90791748‏
996 ‎‡2  RERO|A009036941‏
996 ‎‡2  LC|no2010019348‏
996 ‎‡2  BNC|981061020346706706‏
996 ‎‡2  BNE|XX1240990‏
996 ‎‡2  BNE|XX1240992‏
996 ‎‡2  SUDOC|236448900‏
996 ‎‡2  NTA|06766461X‏
996 ‎‡2  BNE|XX4932304‏
996 ‎‡2  BNE|XX1002137‏
996 ‎‡2  BNCHL|10000000000000000189452‏
996 ‎‡2  LC|no2001070880‏
996 ‎‡2  ISNI|0000000035383196‏
996 ‎‡2  ARBABN|000063758‏
996 ‎‡2  ISNI|0000000060198929‏
996 ‎‡2  DNB|13798877X‏
996 ‎‡2  ISNI|0000000078259697‏
996 ‎‡2  BNE|XX1167960‏
996 ‎‡2  BIBSYS|10026037‏
996 ‎‡2  ISNI|0000000394631358‏
996 ‎‡2  DNB|1325825964‏
996 ‎‡2  LC|n 2017031945‏
996 ‎‡2  ISNI|0000000059628696‏
996 ‎‡2  PLWABN|9810676315105606‏
996 ‎‡2  BNE|XX1036211‏
996 ‎‡2  DNB|1263804896‏
996 ‎‡2  BNC|981058511922306706‏
996 ‎‡2  NUKAT|n 2013075272‏
996 ‎‡2  NTA|370151275‏
996 ‎‡2  BNE|XX1597871‏
996 ‎‡2  BNE|XX942991‏
996 ‎‡2  DNB|137864191‏
996 ‎‡2  BNCHL|10000000000000000222999‏
996 ‎‡2  LC|n 97011075‏
996 ‎‡2  BNCHL|10000000000000000122439‏
996 ‎‡2  BNCHL|10000000000000000111959‏
996 ‎‡2  DNB|141204346‏
996 ‎‡2  LC|n 00102908‏
996 ‎‡2  DNB|128652780‏
996 ‎‡2  BNE|XX4857227‏
996 ‎‡2  ISNI|0000000059627925‏
996 ‎‡2  BNF|14649607‏
996 ‎‡2  LC|nb2003101859‏
996 ‎‡2  LC|n 94017314‏
996 ‎‡2  BNE|XX5281529‏
996 ‎‡2  BNE|XX827604‏
996 ‎‡2  SELIBR|195273‏
996 ‎‡2  BIBSYS|90344609‏
996 ‎‡2  BNC|981058525265806706‏
996 ‎‡2  DNB|1019960132‏
996 ‎‡2  BNCHL|10000000000000000262733‏
996 ‎‡2  BNC|981058524955006706‏
996 ‎‡2  BNE|XX942849‏
996 ‎‡2  BNE|XX5641248‏
996 ‎‡2  LC|n 2006095113‏
996 ‎‡2  ISNI|0000000107836490‏
996 ‎‡2  BNC|981058519879106706‏
996 ‎‡2  LC|no2020063356‏
996 ‎‡2  BNE|XX4613181‏
996 ‎‡2  SUDOC|030425654‏
996 ‎‡2  BLBNB|000608908‏
996 ‎‡2  PTBNP|1674137‏
996 ‎‡2  BNE|XX921200‏
996 ‎‡2  LC|no2020107065‏
996 ‎‡2  BNE|XX924365‏
996 ‎‡2  LC|no2002083436‏
996 ‎‡2  PLWABN|9810637092105606‏
996 ‎‡2  ISNI|0000000384810520‏
996 ‎‡2  DNB|1056356073‏
996 ‎‡2  SUDOC|163837821‏
996 ‎‡2  J9U|987007428942705171‏
996 ‎‡2  BNE|XX5033876‏
996 ‎‡2  BNE|XX4923199‏
996 ‎‡2  ISNI|0000000067068617‏
996 ‎‡2  LC|no2007143174‏
996 ‎‡2  BNE|XX1639862‏
996 ‎‡2  BNE|XX5391834‏
996 ‎‡2  NLR|RU NLR AUTH 7762971‏
996 ‎‡2  ISNI|0000000117720440‏
996 ‎‡2  BNCHL|10000000000000000093087‏
996 ‎‡2  PTBNP|157080‏
996 ‎‡2  DNB|1055779639‏
996 ‎‡2  BNF|15060615‏
996 ‎‡2  BNC|981058519799806706‏
996 ‎‡2  LC|n 99001462‏
996 ‎‡2  BNE|XX1530604‏
996 ‎‡2  BNE|XX1260010‏
996 ‎‡2  BNF|17852677‏
996 ‎‡2  DNB|1037765826‏
996 ‎‡2  DNB|1057271381‏
996 ‎‡2  ISNI|0000000026798197‏
996 ‎‡2  ISNI|0000000080910055‏
996 ‎‡2  BNCHL|10000000000000000094741‏
996 ‎‡2  RERO|A018550173‏
997 ‎‡a  0 0 lived 0 0‏ ‎‡9  1‏